- Investing.com
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; training; investment advisory; technology development; project; information; and investing services, as well as the import and export of pharmaceutical products. The company has license agreement with GSK plc to develop up to 12 innovative medicines in respiratory, immunology and inflammation, and oncology areas. Jiangsu Hengrui Medicine Co., Ltd. was founded in 1970 and is headquartered in Lianyungang City, China.
Metrics to compare | 600276 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600276PeersSector | |
---|---|---|---|---|
P/E Ratio | 59.7x | 17.5x | −0.5x | |
PEG Ratio | 1.07 | 0.09 | 0.00 | |
Price/Book | 8.7x | 2.5x | 2.6x | |
Price / LTM Sales | 14.0x | 3.0x | 3.3x | |
Upside (Analyst Target) | 14.4% | 5.7% | 45.1% | |
Fair Value Upside | Unlock | 18.6% | 7.4% | Unlock |